ArticleExpert opinion on biological therapy2020
Will plant-made biopharmaceuticals play a role in the fight against COVID-19?
Article in Expert opinion on biological therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID-19, a multicenter open-labeled, randomized, controlled clinical trial.Phytotherapy research : PTR · 2021Trial
- Usage of Natural Health Products (NHPs) for respiratory diseases: user characteristics and NHP-Consumption behavior during the Covid-19 pandemic in Germany.BMC complementary medicine and therapies · 2023Article
- Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.Vaccine · 2023Article
- Generation of multi-layered protein bodies inFrontiers in plant science · 2023Article
- Plant-made vaccines against viral diseases in humans and farm animals.Frontiers in plant science · 2023Review
- Rapid Transient Expression of Receptor-Binding Domain of SARS-CoV-2 and the Conserved M2e Peptide of Influenza A Virus Linked to Flagellin inPlants (Basel, Switzerland) · 2022Article
- Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong public health and research perspectives · 2022Article
- Development of plant-made monoclonal antibodies against viral infections.Current opinion in virology · 2022Review
- Plant-Derived Recombinant Vaccines against Zoonotic Viruses.Life (Basel, Switzerland) · 2022Review
- Plant-derived natural products for drug discovery: current approaches and prospects.The Nucleus : an international journal of cytology and allied topics · 2022Review
- Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.Biotechnology letters · 2022Review
- Contributions of the international plant science community to the fight against human infectious diseases - part 1: epidemic and pandemic diseases.Plant biotechnology journal · 2021Review
- Contributions of the international plant science community to the fight against infectious diseases in humans-part 2: Affordable drugs in edible plants for endemic and re-emerging diseases.Plant biotechnology journal · 2021Review
- Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.Vaccines · 2021Review
- COVID-19 vaccines and nanomedicine.International journal of dermatology · 2021Review
- Review
- A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov.Molecules (Basel, Switzerland) · 2021Review
- Metabolic effects of agro-infiltration on N. benthamiana accessions.Transgenic research · 2021Article
- Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.Journal of nanobiotechnology · 2021Review
- COVID-19 Crisis: How Can Plant Biotechnology Help?Plants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the dramatic impact of the COVID-19 pandemic, it is imperative to divulge all the available technologies with the potential to fight against this virus. Plant biotechnology offers potential solutions to this pandemic through the development of low-cost vaccines and antibodies useful for therapy, prophylaxis, and diagnosis. The technology to produce plant-made biopharmaceuticals is already established; two examples of these are: a therapeutic enzyme that has entered the market and the influenza vaccines that are currently under clinical trials with encouraging results. Thus far, some companies have started developing anti-COVID-19 antibodies and vaccines. In particular, plant-made antibodies might be timely produced and approved for human use in the short term, while the development of vaccines will take longer time (clinical evaluations could be concluded by the end of 2021); nonetheless, the candidates obtained will be valuable tools for future outbreaks. The key aspects that will define the exploitation of this technology in the fight against COVID-19 are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.